The field of genomics in myeloid malignancies and related implications in AML are evolving rapidly, and induction treatment strategies are now often guided by biological disease factors and fitness for intensive induction therapy. Familiarity with up-to-date risk stratification and targeted therapies is essential when formulating induction treatment strategies for newly diagnosed AML. 

The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with AML.

Clinicians need education regarding which patients with leukemia are candidates for genetic counseling and testing and how the management of patients with known germline mutations is affected. This knowledge will help clinicians provide these patients with optimal care.

To help patients have the best outcomes possible, clinicians need education on selection of therapy (high-intensity, low-intensity, or targeted) and on how best to manage toxicities and provide supportive care.

The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with AML.

The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with AML.

Recent studies are demonstrating the utility of novel agents and modifications to existing regimens as viable first-line options in early- and advanced-stage HL. An awareness of the clinical studies evaluating the utility of these treatment modalities will help oncology clinicians determine how to optimally incorporate them into the standard of care for patients and improve patient outcomes.

Treatment options should be individualized for patients with relapsed/refractory mantle cell lymphoma (MCL). The selection of optimal second-line therapy depends on the age and fitness of the patients as well as the eligibility for transplant. In the absence of standard management, patients with relapsed/refractory MCL, particularly those who are not eligible for transplant, should be referred for participation in prospective clinical trials investigating novel treatment regimens.

Informing clinicians about therapeutic advances will aid in their incorporation into standard treatment protocols for the appropriate subgroups of patients with AML.